RWE’s Biggest Role In US FDA Approvals: External Controls For Breakthrough Rare Disease Therapies
When the US FDA relies on real-world evidence, it is most commonly for rare disease applications with breakthrough designations. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images
